QuickLinks -- Click here to rapidly navigate through this document

*** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER 17
C.F.R. SECTIONS 200.80(B)(4) AND 230.406.

Exhibit 10.80

Confidential

Chemistry Products and Services Agreement

        The parties, Pfizer Inc, a Delaware corporation, having a place of
business at 235 East 42nd Street, New York, New York 10017 and its Affiliates
("Pfizer") and Discovery Partners International, Inc, a Delaware corporation,
having a place of business at 9640 Towne Centre Drive, San Diego, CA 92121 and
its Affiliates ("DPI") enter into this Chemistry Products and Services Agreement
as of January 5, 2004 (the "Agreement") to provide Pfizer with chemistry
products and services, that may include but are not limited to development of
protocols and procedures useful in the production of pharmaceutically relevant
compounds, to design and synthesize libraries of Pfizer exclusive compounds for
Pfizer's chemical files, penultimate compounds, lead libraries, monomers and
templates, and other services from time to time on the terms and subject to the
conditions set forth below.

1.    DEFINITIONS.

        Whenever used in this Agreement, the terms defined in this Section 1
shall have the meanings specified as set forth below:

        1.1    "Affiliates" means any corporation or other legal entity owning,
directly or indirectly, fifty percent (50%) or more of the voting capital shares
or similar voting securities of Pfizer or DPI; any corporation or other legal
entity fifty percent (50%) or more of the voting capital shares or similar
voting rights of which is owned, directly or indirectly, by Pfizer or DPI or any
corporation or other legal entity fifty percent (50%) or more of the voting
capital shares or similar voting rights of which is owned, directly or
indirectly, by a corporation or other legal entity which owns, directly or
indirectly, fifty percent (50%) or more of the voting capital shares or similar
voting securities of Pfizer or DPI.

        1.2    "Agreement Period" means the period beginning on the Effective
Date and ending two (2) years later, unless extended by mutual agreement of the
parties.

        1.3    "Annual Budget" means the amount of money that Pfizer commits to
fund the Annual Project Plan for any individual Commitment Year as provided in
the Annual Project Plan.

        1.4    "Annual Project Plan" means the written plan describing the
research in the Area to be carried out during each Commitment Year by Pfizer and
DPI pursuant to this Agreement,

--------------------------------------------------------------------------------

unless modified during the Commitment Year by the Steering Committee. Each
Annual Project Plan will be agreed to by the parties and attached to and made a
part of this Agreement as Exhibit A.

        1.5    "Area" means research and development of synthetic processes,
procedures or protocols for synthesis and purification of compounds, generation
of Virtual Libraries and the production and purification of Tangible Libraries,
MT Compounds, and Penultimates, as well as the development or modification of
Protocols and Other Services such as, but not limited to, computational work as
specified in the Annual Project Plans or Work Orders as agreed to between the
parties from time to time.

        1.6    "Commitment Year" means a twelve (12) month period commencing on
the Effective Date and each anniversary thereafter.

        1.7    "Compound" means any individual chemical compound that is an FE
Compound, LL Compound, MT Compound, HF Compound or a Penultimate.

        1.8    "DPI Confidential Information" means all confidential information
about any element of the DPI Technology that is disclosed by DPI to Pfizer and
designated "Confidential" in writing by DPI at the time of disclosure or within
thirty (30) days following disclosure.

        1.9    "DPI Technology" means, Technology that is or was developed or
acquired by employees of or consultants to DPI alone or jointly with third
parties prior to the Effective Date, or after the Effective Date in the course
of activities not related to the Project Plan or Project Program. For the
purposes of the disclosure by DPI to Pfizer of DPI Technology, such disclosure
specifically excludes [ *** ] related to [ *** ] thereon that may be developed
or acquired by employees of or consultants to DPI.

        1.10    "Effective Date" is January 5, 2004.

        1.11    "Events of Termination for Cause" means events of termination
for cause as further defined in Section 17.2.

        1.12    "Expiration Date" is January 5, 2006 unless extended by the
parties.

        1.13    "File Enrichment Compound" or "FE Compound" means any individual
chemical compound derived from an FE Library.

        1.14    "File Enrichment Library" or "FE Library" means a Tangible
Library and Virtual Library of chemical compounds generated pursuant to this
Agreement and with the chemical compound and Library specifications set forth in
the Specifications Schedule.

        1.15    "Full Time Equivalent" ("FTE") means the amount of work
equivalent to a full time employee working on a full time basis consistent with
normal business and scientific practice (who works at least a forty (40) hour
work week with normal vacation, holiday and sick time) working for DPI for a
period of one (1) year.

*** Confidential Treatment Requested

2

--------------------------------------------------------------------------------

        1.16    "FTE month" means the amount of work equivalent to one twelfth
(1/12) of an FTE.

        1.17    "FTE Services" means the work efforts by a common FTE pool to
prepare and deliver MT Compounds and HF Compounds (other than HF Processing) as
further described in Section 2.4.3 and Other Services, in accordance with the
Annual Project Plan and funded by Pfizer.

        1.18    "Hit Follow Up Compound" or "HF Compound" means any individual
chemical compound derived from an HF Library.

        1.19    "Hit Follow Up Library" or "HF Library" means a Tangible Library
of chemical compounds generated pursuant to this Agreement and with the chemical
compound and Library specifications set forth in the Specifications Schedule.

        1.20    "Hit Follow Up Processing" or "HF Processing" means the tasks
performed by DPI associated with the purification, packaging and shipping of the
HF Compounds.

        1.21    "Hit Follow Up Services" or "HF Services" means the use and
combination of FTE Services with HF Processing required to prepare and deliver
HF Compounds.

        1.22    "Large Library Compound" or "LL Compound" means any individual
chemical compound derived from an LL Library.

        1.23    "Large Library" or "LL Library" means a Tangible Library (in
general to be larger than an FE Library) of chemical compounds generated
pursuant to this Agreement and with the chemical compound and Library
specifications set forth in Specifications Schedule.

        1.24    "Library" means a set of related chemical compounds contemplated
by a Protocol.

        1.25    "Light Compound" means any HF Compound, LL Compound or FE
Compound meeting its respective specifications as a "Light Compound" as set
forth in the Specifications Schedule.

        1.26    "Monomer and Template Compound" or "MT Compound" means the
chemical compound generated pursuant to this Agreement and resulting from a
protocol, literature, structure, starting material or other source with the
specifications set forth in Specifications Schedule.

        1.27    "Other Services" means services, in addition to those provided
for in this Agreement at the Effective Date, that are provided by DPI for Pfizer
from time to time, such as work which is in addition to that contemplated by the
Annual Project Plan and Annual Budget, computational chemistry and other work,
agreed to by the parties and as expressed in a written Work Order and funded or
paid for by Pfizer with funds incremental to the Annual Budget.

        1.28    "Patent Rights" means all patent rights within Technology
including all of patent applications, whether domestic or foreign, claiming such
patentable inventions, continuations,

3

--------------------------------------------------------------------------------

continuations-in-part, divisions, and renewals, all letters patent granted
thereon, and all reissues, re-examinations and extensions thereof.

        1.29    "Penultimate" means an individual chemical entity, which is a
stable chemical compound of a synthetic step nearest to, but not equal to the
final product of the synthetic route, within a Tangible Library.

        1.30    "Pfizer Confidential Information" means all confidential
information about any element of Pfizer Technology that is disclosed by Pfizer
to DPI and designated "Confidential" in writing by Pfizer at the time of
disclosure or within thirty (30) days following disclosure. In addition, Pfizer
Confidential Information includes items listed in Section 10.1.1, Pfizer Inputs
delivered by Pfizer to DPI, and this Agreement, its attachments and Exhibits.

        1.31    "Pfizer Inputs" means the [ *** ], and any other tangibles or
non-tangibles that are scheduled to be delivered by Pfizer to DPI in an Annual
Project Plan or are necessary or desirable for Pfizer to provide and or deliver
to DPI in order for DPI to complete the goals and deliverables provided by
Pfizer to DPI as scheduled in the Annual Project Plan. The Pfizer Inputs and the
timing of their delivery from Pfizer to DPI will be identified in the Annual
Project Plan.

        1.32    "Pfizer Technology" means, Technology that is or was developed
or acquired by employees of or consultants to Pfizer alone or jointly with third
parties prior to the Effective Date, or after the Effective Date in the course
of activities not related to the Project Plan or Project Program.

        1.33    "Program Technology" means Technology that is or was developed
or acquired by employees of or consultants to Pfizer or DPI solely or jointly
with each other in the course of performing the Project Plan and that relates to
[ *** ] scheduled to be delivered by [ *** ] in accordance with the [ *** ]
[ *** ] and specifically excludes [ *** ] [ *** ].

        1.34    "Project Plan" means the applicable Annual Project Plan for each
Commitment Year of the Agreement Period.

        1.35    "Project Program" means the collaborative work in the Area
conducted by Pfizer and DPI pursuant to the Annual Project Plans.

        1.36    "Protocol" means a detailed set of methods and standard
operating procedures designed to be used for synthesis and purification,
including but not limited to HPLC purification, of a Compound.

        1.37    "Specifications Schedule" means the schedule attached to and
made part of this Agreement entitled the Specifications Schedule that identifies
the specifications of the Compounds and their design and other criteria that are
targeted to be met by the appropriate party as modified and agreed to by the
Steering Committee from time to time.

        1.38    "Steering Committee" means the committee comprised of an equal
number of Pfizer and DPI employees that direct the Project Plan and have other
responsibilities as further defined in Section 6.3.

*** Confidential Treatment Requested

4

--------------------------------------------------------------------------------

        1.39    "Tangible Library" means a group of related FE Compounds, LL
Compounds or HF Compounds synthesized by DPI as requested by Pfizer under this
Agreement.

        1.40    "Technology" means and includes all [ *** ] that includes, but
is not limited to, [ *** ], within the Area.

        1.41    "Virtual Library" means a set of FE Compounds that are described
by [ *** ].

        1.42    "Work Order" means a written description of products, work or
services that DPI will provide to Pfizer from time to time, on terms and
conditions that are agreed to between the parties that is in addition to the
work described in the Annual Project Plan and funded or paid for by Pfizer with
funds incremental to the Annual Budget for any given Commitment Year.

2.    SCOPE OF WORK.

        2.1    Annual Project Plan. The Annual Project Plans for [ *** ] and
[ *** ] are approved by the parties and attached to and made part of this
Agreement as Exhibit A. The Annual Project Plan, for any Commitment Year
subsequent to [ *** ], if the parties mutually agree to extend the Agreement
Period beyond the contemplated [ *** ] years, will be prepared and agreed to,
but not approved, by the Steering Committee and shall include at least the
following elements:

a)the contemplated annual budget, subject to approval per Section 3, for the
Annual Project Plan; and

b)the anticipated work (FE Compounds [ *** ], LL Compounds, HF Compounds, and MT
Compounds) to be completed in a given Commitment Year; and

c)the metrics, to evaluate the work, which are specific, measurable, accurate,
reliable and timely (where applicable); and

d)the schedule, on a quarterly basis, for the delivery of FE Compounds and
related Penultimates; and

e)the schedule, on a quarterly basis, for the delivery of LL Compounds; and

f)the schedule, on a quarterly basis, for the amount of HF Processing capacity
that DPI shall provide during the Commitment Year; and

g)the schedule, on a quarterly basis, for the number of FTEs that DPI will
provide to complete FTE Services during the Commitment Year; and

h)the Pfizer Inputs, the means by which they shall be delivered to and accepted
by DPI, and the timing of their delivery; and

i)other items as mutually agreed to by the Steering Committee.

        2.2    Management of and Changes to an Annual Project Plan by Steering
Committee.

        2.2.1    Management of the Annual Plan. The Steering Committee will
manage the Annual Project Plan. Work done under the Annual Project Plan will be
monitored by the Steering Committee and progress of the work may be compared to
the scheduled quarterly work in the Annual Project Plan.

        2.2.2    Changes to an Annual Project Plan. Changes to the work in the
Annual Project Plan (FE Compounds, LL Compounds, HF Compounds, and MT Compounds
or

*** Confidential Treatment Requested

5

--------------------------------------------------------------------------------

other agreed to substitute within the Area) can be contemplated by the Steering
Committee and the budget can be reallocated amongst the various types of work in
the Project Program provided that:

a)the Steering Committee approves; and

b)the [ *** ]; and

c)the budget planned in any individual calendar quarter is [ *** ] that
contemplated in the Annual Project Plan.

        2.3    Timing of Approval to the Annual Project Plan. The [ *** ] and
[ *** ] Annual Project Plans are approved by the parties and are attached to
this Agreement as Exhibit A. If the parties mutually agree to extend the
Agreement Period beyond the contemplated [ *** ] years, as described in
Section 3.1.3, the Steering Committee shall prepare and agree to all future
Annual Project Plans not later than [ *** ], and approve of all future Annual
Project Plans not later than [ *** ] of the year preceding the Commitment Year
of such Annual Project Plan.

        2.4    Deliverables under the Annual Project Plan. The Annual Project
Plan will set forth the deliverables that DPI will provide; to include the
deliverable schedule, to Pfizer during the Commitment Year. The Annual Project
Plan will also set forth Pfizer Inputs that Pfizer will provide, the deliverable
schedule, to DPI during the Commitment Year, such that DPI can perform the work.
Pfizer shall use reasonable commercial efforts to provide the Pfizer Inputs
within the timeframes contemplated in the Annual Project Plan.

        2.4.1    FE Program. DPI shall use reasonable commercial efforts to
deliver the full number of FE Compounds in general accordance, [ *** ] in any
quarter, with the schedule set forth in the Annual Project Plan for any given
Commitment Year. Subject to Section 3.5, Pfizer shall not be obligated to pay,
in accordance to Section 3.2, for any FE Compounds in excess of the number of FE
Compounds scheduled to be delivered in the Annual Project Plan for such
Commitment Year. DPI shall bear the cost of delivery of the FE Compounds. In
connection with the delivery of FE Compounds, DPI shall also deliver to Pfizer,
on a FE Library basis:

a)[ *** ]; and

b)an [ *** ] and [ *** ]

c)[ *** ]; and

d)[ *** ].

        2.4.2    LL Program. DPI shall use reasonable commercial efforts to
deliver the full number of LL Compounds in general accordance, [ *** ] in any
quarter, with the schedule set forth in the Annual Project Plan for any given
Commitment Year. Pfizer shall not be obligated to pay, in accordance to
Section 3.2, for any LL Compounds in excess of the number of LL Compounds
scheduled to be delivered in the Annual Project Plan for such Commitment Year.
DPI shall bear the cost of delivery of the LL Compounds. In connection with the
delivery of the LL Compounds, DPI shall also deliver to Pfizer:

a)[ *** ]; and

b)[ *** ]; and

c)[ *** ].

*** Confidential Treatment Requested

6

--------------------------------------------------------------------------------

        2.4.3    FTE Services Program (HF Compounds and MT Compounds).

a)DPI shall use FTE Services to complete MT Compounds that DPI prepares and
delivers to Pfizer under the Annual Project Plan. As further described in
subsection b) below, DPI shall use both FTE Services and HF Processing capacity
to complete HF Compounds that DPI prepares and delivers to Pfizer under the
Annual Project Plan. As agreed to by the Steering Committee, the FTEs will be
assigned to complete the objectives of the Annual Project Plan prioritized as
follows:

i)all [ *** ] associated with the [ *** ] of [ *** ]); and

ii)[ *** ]; and

iii)[ *** ].

b)Delivery of HF Compounds. All of DPI's efforts to prepare, complete and
deliver HF Compounds to Pfizer (other than the work effort directly associated
with HF Processing) will be provided as part of the FTE Services. DPI will
deliver HF Compounds that result from HF Services. DPI shall bear the cost of
delivery of the HF Compounds. DPI will use reasonable commercial efforts to
deliver as part of the HF Services, the following:

i)[ *** ]; and

ii)[ *** ]; and

iii)[ *** ].

c)Delivery of MT Compounds. All of DPI's efforts to prepare, complete and
deliver MT Compounds to Pfizer will be provided as part of the FTE Services. DPI
will deliver the MT Compounds that result from such FTE Services. DPI shall bear
the cost of delivery of the MT Compounds. DPI will use reasonable commercial
efforts to deliver the following:

i)[ *** ]; and

ii)[ *** ]. [ *** ]; and

iii)[ *** ].

        2.4.4    Other Services. From time to time, Pfizer may request Other
Services, which will be completed by DPI on the basis of Work Orders, where such
Work Orders, and associated budget, shall be approved by the parties and
attached to and made part of this Agreement as Exhibit B. The deliverables and
budget schedules for Other Services shall be set forth in the applicable Work
Order.

3.0    ANNUAL BUDGET

        3.1    Annual Budgets. For each Commitment Year, the parties shall
prepare a budget based on the Annual Project Plan for that year. The Annual
Budgets for [ *** ] and [ *** ] are approved by the parties and are attached to
this Agreement as part of Exhibit A. Unless the parties agree to amend the
Annual Budgets for [ *** ] or [ *** ] in writing, where such amendment may only
increase the Annual Budget(s), the amount set forth in the Annual Budgets shall
be the amount payable by Pfizer for work covered by the Annual Project Plan
provided that DPI fulfills its obligations under the Annual Project Plan and
this Agreement. If the [ *** ] to

*** Confidential Treatment Requested

7

--------------------------------------------------------------------------------

[ *** ] then for [ *** ] the [ *** ] will [ *** ] the [ *** ] to [ *** ] and
[ *** ] the [ *** ] to be [ *** ] by [ *** ].

        3.1.1    [ *** ] Annual Budget. The Annual Budget for the [ *** ] Annual
Project Plan is [ *** ]).

        3.1.2    [ *** ] Annual Budget. The Annual Budget for the [ *** ] Annual
Project Plan is [ *** ]). The 2005 Annual Budget, if greater than ($[ *** ]),
will be agreed to by the parties no later than [ *** ].

        3.1.3    [ *** ] Annual Budget. If the parties agree to extend the
Agreement Period in [ *** ], Pfizer will provide Notice to DPI of an approved
Annual Budget, by [ *** ] and/or [ *** ] respectively.

        3.2    Funding under the Annual Budget. The Annual Budget describes the
funds that Pfizer shall provide for a Commitment Year on a quarterly basis.

        3.2.1    FE and LL Compounds. Subject to Sections 2.2.2 and 2.4, for any
Annual Project Plan under which DPI has committed to deliver FE Compounds or LL
Compounds, the corresponding Annual Budget will reflect the type of such
Compounds (whether FE or LL), the number of each type of such Compounds to be
delivered, and the delivery schedule; and will provide for Pfizer to pay DPI an
amount equal to the sum of: (a) for [ *** ], the [ *** ] the [ *** ] plus
(b) for [ *** ] the [ *** ] the [ *** ]. For Commitment Years [ *** ] and
[ *** ], the FE Compound payment amount is [ *** ] per FE Compound and the LL
Compound payment amount is [ *** ] per LL Compound.

        3.2.2    HF Compounds.

a)Subject to Sections 2.2.2, and 2.4, for any Annual Project Plan under which
DPI is scheduled to provide HF Services, the corresponding Annual Budget will
reflect the amount of reserved HF Processing capacity and the availability of
such; and will provide for Pfizer to pay DPI an amount equal to the [ *** ] the
[ *** ] of [ *** ] which [ *** ] the [ *** ] the [ *** ]. For Commitment Years
[ *** ] and [ *** ], the rate for HF Processing is [ *** ] per each HF Compound
scheduled to be started in synthesis.

b)Pfizer shall fund HF Processing for each calendar quarter of each Annual
Project Plan based upon the HF Processing capacity scheduled in such quarter,
provided that DPI reserves and makes available to Pfizer sufficient HF
Processing capacity to complete the HF Compounds scheduled to be started in such
quarter. Each party will allocate the HF Processing work and corresponding HF
Processing capacity on a level basis during each quarter unless the Steering
Committee otherwise agrees. Pfizer shall be entitled to receive all HF Compounds
meeting specifications that are output from HF Processing in a quarter whether
above or below the performance metrics that are agreed to from time to time by
the Steering Committee. Pfizer shall also pay for, [ *** ].

*** Confidential Treatment Requested

8

--------------------------------------------------------------------------------

        3.2.3    FTEs Services Program. Subject to Sections 2.2.2 and 2.4, for
any Annual Project Plan under which DPI has committed to provide FTE Services,
the corresponding Annual Budget will reflect the number of such FTEs and provide
an amount that Pfizer is to pay DPI which equals the product of the number of
FTEs times the applicable FTE rate. For Commitment Years [ *** ] and [ *** ],
the applicable FTE rate is [ *** ]. Pfizer agrees to fund the FTEs provided that
DPI makes the requisite number of FTEs available to Pfizer in accordance with
the quarterly schedule set forth in the Annual Project Plan.

        3.2.4    Other Services Deliverables. The deliverables for Other
Services and the funding and payments associated with Other Services shall be
set forth in the applicable Work Order.

        3.3    Rate of Payment for [ *** ]. The rate of payment for FE
Compounds, LL Compounds, FTE Services and HF Processing, if the parties agree to
extend the Agreement Period, shall be at the approval of the parties and shall
be included in the respective [ *** ] Annual Project Plan.

        3.4    Pfizer's Payment. Pfizer's aggregate payment obligation under the
Annual Budget shall equal the sum of the amounts determined in accordance with
Sections 3.2 and shall be subject to reconciliation with the obligations DPI
actually fulfilled during the Commitment Year as provided in Section 4.1.

        3.5    [ *** ] Delivery Option of FE Compounds or LL Compounds in
[ *** ]. [ *** ] shall have the [ *** ], to [ *** ] (the "[ *** ]") during
[ *** ]. The [ *** ] of [ *** ] that can be [ *** ] by [ *** ] during [ *** ]
shall [ *** ]. If [ *** ] to [ *** ], it will [ *** ] of [ *** ] on or after
[ *** ]. If [ *** ] and [ *** ] then [ *** ] will be [ *** ] to [ *** ] for
[ *** ]. [ *** ] for [ *** ] shall be [ *** ] in the [ *** ] of [ *** ].

4.0    PAYMENT, PROCESSING, RECONCILIATION AND RELATED MATTERS

        4.1    Payment for Deliverables and Services. Payments by Pfizer to DPI
against the Annual Budget for the Annual Project Plan in a given Commitment Year
will be made according to the following schedule: (a) within [ *** ] of the
Effective Date and each anniversary thereafter, [ *** ] of the Annual Budget
shall be paid to DPI by Pfizer against a DPI invoice and such [ *** ] shall be
applied equally among the four (4) quarterly invoices payable in accordance with
Section 4.2, and (b) the remaining balance owed by Pfizer in any Commitment
Year, shall be paid to DPI against a quarterly invoice from DPI as described in
Section 4.2. Pfizer agrees to pay these funds to DPI provided that DPI fulfils
its obligations to Pfizer under this Agreement for the applicable quarterly
period for which payment was due.

        In connection with each invoice for each quarter and for the Commitment
Year, DPI shall report to Pfizer the DPI deliverable obligations, which are:

(i)the FE Compounds delivered to Pfizer that met the criteria set forth in the
Specifications Schedule; and,

*** Confidential Treatment Requested

9

--------------------------------------------------------------------------------

(ii)the LL Compounds delivered to Pfizer that met the criteria set forth in the
Specifications Schedule; and,

(iii)the HF Processing capacity made available to Pfizer; and,

(iv)the number of FTEs made available to Pfizer; and,

(v)any itemized charges with respect to Other Services under Section 3.2 and
back charged materials in accordance with Section 4.4; and,

        In addition, DPI invoice will report the itemized output from the
deliverable obligation under the Annual Project Plan, which are:

(i)[ *** ]; and,

(ii)[ *** ]; and,

(iii)such other information that may reasonably be requested by Pfizer.

        Within [ *** ] days of the delivery of the invoice to Pfizer, the
parties will reconcile the FTE Services performed, the HF Processing capacity
provided and the FE and LL Compounds delivered against the Annual Budget. If
there is a dispute of any invoiced amount, Pfizer shall pay any amount not in
dispute and the parties will use reasonable commercial efforts to reconcile any
other amounts due and payable based on the delivery of goods and the provision
of services by DPI to Pfizer in accordance with the terms of this Agreement for
the applicable period. During the review of the fourth and final invoice for the
Commitment Year, the parties will reconcile all four (4) invoices for the
Commitment Year. If the result is positive, the corresponding amount shall be
due from Pfizer to DPI. If the result is negative, the corresponding amount
shall be due from DPI to Pfizer.

        4.2    Quarterly Invoices. In order for DPI to receive payment, DPI will
prepare and deliver to Pfizer one (1) invoice for a calendar quarter and deliver
it to Pfizer. Each invoice shall list the Pfizer purchase order number, the
dates being invoiced, the relevant Pfizer project code and the report described
in Section 4.1. Invoices shall be submitted to Pfizer within [ *** ] of the
close of a payment quarter, or sooner, as described below, in the event of
termination. DPI's invoices shall be sent to: Pfizer Global Research and
Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, Attention: [ *** ],
or other Pfizer designate, with a copy to Pfizer Global Research and
Development, 50 Pequot Avenue, New London, Connecticut 06320, Attention:
[ *** ], or other Pfizer delegate.

        4.3    Payment by Pfizer. Each payment made by Pfizer pursuant to this
Agreement shall be paid in U.S. currency by wire transfer in immediately
available funds to an account designated by DPI, or by other mutually acceptable
means, within [ *** ] after receipt and acceptance by Pfizer of the invoice from
DPI.

        4.4    Cost of Materials.

        4.4.1    Pfizer will provide DPI with Pfizer Inputs as indicated in the
Annual Project Plan, in connection with the development and synthesis of
Compounds. With the exception of Pfizer Inputs, DPI will be responsible for
acquiring [ *** ]. If however, [ *** ]. If [ *** ].

        4.4.2    If DPI requires specialty materials with Compounds such as
[ *** ].

*** Confidential Treatment Requested

10

--------------------------------------------------------------------------------

        4.4.3    [ *** ] and [ *** ] will be provided by DPI for [ *** ]. This
includes but is not limited to the following [ *** ]. By way of examples, this
includes but is not limited to [ *** ]

        4.4.4    [ *** ] will be provided by DPI.

        4.4.5    [ *** ] requested by Pfizer that [ *** ].

        4.4.6    The cost of waste disposal will belong to [ *** ].

5.    RECORDS.

        5.1    DPI shall keep for [ *** ] from the conclusion of each Commitment
Year complete and accurate records of its work done under [ *** ], and
expenditures of effort made by DPI and received by Pfizer under [ *** ]. The
records shall conform to good accounting principles as applied to a similar
company similarly situated. Pfizer shall have the right at its own expense
during the term of this Agreement and during the subsequent [ *** ] period to
appoint an independent certified public accountant reasonably acceptable to DPI
to inspect said records with respect to this Agreement provided by DPI to Pfizer
to verify the accuracy of such availability of [ *** ] and [ *** ] with respect
to [ *** ], pursuant to each Project Plan. Upon reasonable notice by Pfizer, DPI
shall make its records available for inspection by the independent certified
public accountant during regular business hours at the place or places where
such records are customarily kept, to verify the accuracy of the expenditures of
efforts. This right of inspection shall not be exercised more than [ *** ] and
not more than [ *** ] covering any specific period of time. All information
concerning such expenditures of efforts, and all information learned in the
course of any audit or inspection, shall be deemed to be DPI Confidential
Information, except to the extent that it is necessary for Pfizer to reveal the
information in order to enforce any rights it may have pursuant to this
Agreement or if disclosure is required by law. The failure of Pfizer to request
verification of any expenditure of efforts before or during the [ *** ] period
shall be considered acceptance by Pfizer of the accuracy of such expenditures of
efforts, and DPI shall have no obligation to maintain any records pertaining to
such report or statement beyond such [ *** ] period. The findings of such
inspection, if any, shall be binding on the parties, subject to a reasonable
opportunity for DPI or Pfizer to object to such findings, based upon reasonable
supporting documentation.

6.    PROJECT PROGRAM.

        6.1    Purpose. DPI and Pfizer shall conduct the Project Program
throughout the Agreement Period in accordance with each Annual Project Plan.

        6.2    Amendment of Project Plans. The Steering Committee shall review
and amend, if necessary, the Annual Project Plan pursuant to Section 2.2. Any
amendments to the Project Plan must be in writing and attached to and made part
of this Agreement as Exhibit A.

        6.3    Steering Committee. Pfizer and DPI shall direct the Project Plan
via the Steering Committee (the "Steering Committee"), which shall perform the
following duties in good faith:

a)prepare each Annual Project Plan; and

*** Confidential Treatment Requested

11

--------------------------------------------------------------------------------

b)prepare and approve any amendments to the Annual Project Plan within a
Commitment Year that are consistent with Section 2.2 and 3.1; and

c)review and evaluate progress under each Annual Project Plan and report to
Pfizer the progress under the Project Program, and Annual Project Plans
according to metrics developed and agreed to by the Steering Committee; and

d)approve, coordinate and monitor activities and staffing; and

e)approve, coordinate, and monitor Technology transfers between parties; and

f)review and approve publications for submission to the parties for approval
pursuant to Section 11; This function shall survive the term of this Agreement;
and

g)develop and approve contingencies, when necessary, to ensure the Annual
Project Plan is on track; and

h)establish and agree upon Other Services to be submitted under this Agreement;
and

i)establish and appoint sub-committees to monitor work to be performed under the
Annual Project Plan.

        6.4    Membership. Pfizer and DPI each shall appoint, in its sole
discretion, four (4) members to the Steering Committee. Substitutes may be
appointed at any time.

        The members initially shall be:

            Pfizer Appointees:
            [ *** ]

            DPI Appointees:
            [ *** ]

        6.5    Chair. The Steering Committee shall be chaired by two
(2) co-chairpersons, one (1) appointed by Pfizer and the other appointed by DPI.
Pfizer, acting responsibly, shall have the right to approve the selection of the
DPI co chairperson.

        6.6    Meetings and Research Contacts.

        6.6.1    Meetings. The Steering Committee shall meet at least quarterly,
at places selected by each party in turn and on dates mutually agreed by the
parties. The first meeting of the Steering Committee, will cover the following:
Roles and responsibilities of the Steering Committee members, confirmation of
Annual Project Plan goals, Project Plan review, tentative meeting schedules for
the quarterly and other meetings, minutes, reports, development of metrics and
contact points. Representatives of Pfizer, or DPI, or both, in addition to
members of the Steering Committee, may, upon the agreement of the other party,
attend such meetings at the invitation and expense of that party when required
to meet the Project Program goals.

        6.6.2    Research Contacts. In addition, the Steering Committee shall
appoint a single contact at DPI and Pfizer ("the Research Contacts") to provide
a written communication to the Steering Committee on a monthly basis detailing
the progress of any existing subcommittees. A consolidated overview of the
monthly communications

*** Confidential Treatment Requested

12

--------------------------------------------------------------------------------

will also be presented by the Research Contacts to the Steering Committee at the
quarterly Steering Committee meeting, with emphasis on progress against goals,
issues, contingency plans (where required) and any open action items. All
communication pertaining to the subcommittees shall be the sole responsibility
of the Research Contacts. The Research Contacts, or a subcommittee designee
shall hold at least biweekly telephone meetings beginning soon after the
Effective Date, and prepare brief minutes of their discussions for distribution
to the Research Contacts for review and approval within [ *** ] of such
meetings. The Pfizer Research Contact shall be responsible for preparing the
minutes and obtaining approval for routing.

        6.7    Minutes. Minutes will be written during the Steering Committee
and distributed promptly after the Steering Committee meetings for review by the
co-chairpersons. Minutes are to be approved by the parties prior to final
acceptance and distribution. Permitted changes to the Annual Project Plan agreed
to by the Steering Committee consistent with the remit under Section 2.2 that
are committed to writing and signed by the co-chairs of the Steering Committee
shall be binding on the parties.

        6.8    Decisions. All decisions of the Steering Committee shall be made
by a unanimous affirmative vote. Notwithstanding the foregoing or any other
provision of this Agreement, the Annual Project Plans may only be amended as
mutually agreed by the Steering Committee pursuant to Section 2.1.

        6.9    Expenses. Pfizer and DPI shall each bear all of their respective
expenses, including reasonable travel, related to the participation of their
respective members of the Steering Committee.

7.    REPORTS AND MATERIALS.

        7.1    Reports. During the Agreement Period, DPI shall furnish to the
Steering Committee summary written reports within [ *** ] after the end of each
calendar quarter, describing the progress under the Project Plan, commencing on
the Effective Date.

        7.2    Materials.

        7.2.1    DPI and Pfizer shall, during the Agreement Period, as a matter
of course as described in the Annual Project Plan, or upon written or oral
request, furnish to each other samples of synthetic chemical materials which are
part of Pfizer Technology, DPI Technology or Program Technology and that are
necessary for each party to carry out its responsibilities under the Annual
Project Plan.

        7.2.2    DPI agrees to provide Compounds and Libraries in accordance
with Section 2.4, and any materials requested by Pfizer when and as approved by
the Steering Committee that pertain to this Agreement. Materials shall be
delivered to a Pfizer designated contact, in a format agreed by the Steering
Committee. DPI shall be responsible for the cost to ship Compounds to a
designated [ *** ] or other location [ *** ].

*** Confidential Treatment Requested

13

--------------------------------------------------------------------------------

8.    LABORATORY FACILITIES and PERSONNEL.

        8.1    DPI shall provide suitable laboratory facilities, equipment and
personnel for the work to be done by DPI in carrying out the Project Program.

9.    COMMERCIALLY REASONABLE EFFORTS.

        9.1    Pfizer and DPI shall each use commercially reasonable efforts to
achieve the objectives of the Project Program. DPI will use commercially
reasonable efforts to achieve the objectives listed in the Project Plan and
Pfizer will use commercially reasonable efforts to assist DPI in each Project
Plan.

10.    TREATMENT OF CONFIDENTIAL INFORMATION

        10.1    Confidentiality. Subject to Section 10.2, DPI and Pfizer agree
that during the Agreement Period, and for [ *** ] thereafter, it will keep
confidential, and will cause its Affiliates, employees, consultants, agents and
sublicensees to keep confidential, all Confidential Information that is
disclosed to it, or to any of its Affiliates, employees, consultants, agents or
sub licensees by the other party pursuant to this Agreement. The term
"Confidential Information" shall mean the DPI Confidential Information or the
Pfizer Confidential Information, as applicable. Each party shall take such
action, and shall cause its Affiliates, employees, consultants, agents and sub
licensees to take such action, to preserve the confidentiality of each other's
Confidential Information as it would customarily take to preserve the
confidentiality of its own Confidential Information. Neither party nor any of
its respective Affiliates, agents or sub licensees shall use the other party's
Confidential Information except as expressly permitted in this Agreement.

        10.1.1    Pfizer Confidential Information. For the purposes of this
Section 10, Program Technology shall be deemed to be Pfizer Confidential
Information. For greater clarity, Program Technology includes (though not
exhaustive):

a)the [ *** ] generated by DPI on behalf of Pfizer; and

b)the [ *** ] part of the [ *** ] and [ *** ]; and

c)the [ *** ] and [ *** ]; and

d)the [ *** ] and [ *** ]; and

e)the [ *** ]; and

f)the modifications by DPI to [ *** ] to perform the work; and

g)the results generated in the performance of Other Services (unless otherwise
modified by the terms of the applicable Work Order).

        For certainty, the fact that [ *** ] relating to any [ *** ], or
requested the [ *** ] of any [ *** ] or that [ *** ] [ *** ] shall be Pfizer
Confidential Information.

        10.2    Permitted Disclosures. Pfizer and DPI each agree that a party
may make disclosure of the other's Confidential Information to its or any of its
Affiliates' officers, employees or agents only if and to the extent necessary to
carry out its responsibilities under this Agreement. Pfizer and DPI each agree
not to disclose the other's Confidential Information to any third parties under
any circumstance without written permission from the other party; provided
however that DPI may, with Pfizer's prior written permission, disclose certain
Pfizer Confidential Information on as-needed basis to its network of third party
sub-contractors engaged in the Project Program when such party is bound by
confidentiality. DPI shall be

*** Confidential Treatment Requested

14

--------------------------------------------------------------------------------

responsible for any breach of the third party's obligation regarding Pfizer
Confidential Information.

        10.3    Return of Confidential Information. Each party, upon the other's
request, will return all the Confidential Information disclosed to it by the
other party pursuant to this Agreement, including all copies and extracts of
documents, within [ *** ] of the request or upon the expiration or termination
of this Agreement except for one (1) copy which may be kept for the purpose of
complying with continuing obligations under this Agreement or permitting the
parties to practice the licenses granted under Section 14.3.

        10.4    Exceptions to Confidentiality. A party's obligation of
nondisclosure and the limitations upon the right to use the Confidential
Information, shall not apply to the extent that it can demonstrate that the
Confidential Information: (a) [ *** ] or (b) [ *** ] or (c) [ *** ]. In
addition, a party shall be entitled to disclose Confidential Information of the
other party to the extent such Confidential Information is the subject of a
demand for disclosure in connection with a legal or administrative proceeding,
in which case such party will give the other party prompt notice of such demand
and will assist the other party if it wishes to seek a protective order or other
remedy with respect to such disclosure demand. To the extent that such party
does not seek, or does not succeed in obtaining, a protective order or other
remedy with respect to such disclosure demand, the other party will comply with
the disclosure demand by disclosing only such portion of Confidential
Information as its legal counsel determines it is required to disclose.

11.    PUBLICATION.

        11.1    Notwithstanding any matter set forth with particularity in this
Agreement to the contrary, results obtained in the course of the Project Program
shall not be published by DPI. Pfizer shall be permitted to publish results
obtained in the course of the Project Program. With respect to DPI, exceptions
to this no publication rule may be made on an individual basis. The Steering
Committee shall consider any requests by DPI for publication at quarterly
Steering Committee meetings. Publications approved by the Steering Committee
shall be subject to final approval by DPI and Pfizer. Final written approval or
disapproval shall be provided within [ *** ] of the Steering Committee
recommendation. DPI publications shall not contain Pfizer Confidential
Information. Pfizer publications shall not contain DPI Confidential Information.

12.    PUBLICITY.

        12.1    Confidentiality of the Agreement. Any information contained in
this Agreement that is confidential information of a party shall remain
confidential information of that party. Except as required by law or regulation,
neither party may disclose the terms of this Agreement nor the services to be
performed pursuant to it without the written consent of the other party,
provided however, that DPI may disclose the terms, or provide copies, of this
Agreement as necessary in the normal course of business to bankers, investors
and others in order to obtain financing or engage in transactions material to
DPI's business, provided that: a) [ *** ]; and b) [ *** ].

        12.2    SEC Filings. Pfizer understands that DPI may be required to file
this Agreement as an exhibit to its public reporting documents filed with the
Securities and Exchange Commission, subject to DPI's intent to request
confidential treatment of certain confidential

*** Confidential Treatment Requested

15

--------------------------------------------------------------------------------

provisions and information in this Agreement. The parties will consult with each
other on the provisions of this Agreement to be redacted in any filings made by
the parties with the Securities and Exchange Commission or as otherwise required
by law.

13.    PERMITTED DISCLOSURE.

        13.1    Disclosure of Inventions. Each party shall promptly inform the
other about all inventions within the Program Technology that are made in the
course of carrying out the Project Program by employees of, or consultants to,
either of them solely, or jointly with employees of, or consultants to the
other.

14.    OWNERSHIP AND INTELLECTUAL PROPERTY RIGHTS.

        14.1    Ownership. [ *** ] and [ *** ] shall be owned solely by [ *** ].
[ *** ] shall solely own [ *** ], [ *** ], and [ *** ].

        14.2    Intellectual Property. Subject to Section 14.1 and 14.3.2,
[ *** ] acknowledges that [ *** ] shall have the [ *** ] [ *** ], to [ *** ]
generated or obtained by [ *** ] on behalf of [ *** ] and any other [ *** ]
[ *** ] by [ *** ] pursuant to the [ *** ] or [ *** ] (except as otherwise
provided in any [ *** ]). [ *** ] shall not disclose [ *** ] to any third party,
nor subject to [ *** ] use [ *** ] for the benefit of [ *** ] [ *** ]. [ *** ]
agrees not to disclose that [ *** ] has [ *** ] for, or the [ *** ]. [ *** ]
will not [ *** ] for or [ *** ] (to include those [ *** ]) to any third party,
so long as the [ *** ] are [ *** ]. [ *** ] shall use [ *** ], [ *** ], and
[ *** ] and any other [ *** ] of the [ *** ], as it sees fit in its course of
business, including all commercial activities without further compensation to
[ *** ].

        14.3    Grants of Research Licenses.

        14.3.1    Subject to the terms and conditions of this Agreement: i),
[ *** ] grants to [ *** ] a [ *** ], [ *** ], to [ *** ] to the extent necessary
to allow [ *** ] [ *** ] and any other [ *** ] of the [ *** ] by [ *** ]
pursuant to the [ *** ] or [ *** ] as it sees fit in its course of business,
including [ *** ]; and, ii) [ *** ] grants to [ *** ] a [ *** ], to [ *** ] that
is provided to [ *** ] in connection with the [ *** ] to the extent such [ *** ]
are necessary to allow [ *** ].

        14.3.2    [ *** ] grants to [ *** ] a [ *** ] solely relating to
[ *** ].

15.    PROVISIONS CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF PATENTS
RIGHTS.

        15.1    DPI shall be solely responsible for [ *** ]. Pfizer shall be
solely responsible for [ *** ].

        15.2    [ *** ] agrees to [ *** ] but without further [ *** ], any
documents necessary for [ *** ] with respect to [ *** ] name. [ *** ] shall,
execute an [ *** ] to [ *** ] with respect to such [ *** ].

*** Confidential Treatment Requested

16

--------------------------------------------------------------------------------

        15.3    [ *** ] shall notify [ *** ] in a timely manner of any [ *** ].
Thereafter, [ *** ] shall have the [ *** ]

        15.4    [ *** ] agrees to complete[ *** ]. [ *** ] shall, [ *** ] to
[ *** ] with respect to the [ *** ]. [ *** ].

16.    ACQUISTION OF RIGHTS FROM THIRD PARTIES.

        16.1    During the Agreement Period, DPI and Pfizer shall each promptly
notify each other of any appropriate opportunities to acquire in any manner from
third parties, technology or patents or information, which it elects to use in
the course of performing the Project Program. DPI and Pfizer shall decide if
such rights should be acquired in connection with the Project Program and, if
so, whether by DPI, Pfizer or both, it being understood that nothing herein
shall obligate either party to obtain such rights or, if it does acquire such
rights, to make such rights available for use in the Project Program. If
acquired such rights shall become part of the Confidential Information,
Technology or Patent Rights, whichever is appropriate, of the acquiring party or
Program Technology, as the case may be.

17.    TERMS, TERMINATION AND DISENGAGEMENT.

        17.1    Term. Unless terminated sooner, as provided below, or extended
by mutual agreement of the parties, this Agreement shall expire on the second
(2nd) anniversary of the Effective Date.

        17.2    Events of Termination for Cause. The following events shall
constitute events of termination for cause ("Events of Termination for Cause"):
i) if any representation, warranty or covenant by DPI or Pfizer in Sections 18
and 19 of this Agreement shall prove to have been incorrect in any material
respect when made; or ii) DPI or Pfizer shall breach any material term, or
covenant contained in this Agreement or in any of the Exhibits attached to it,
and any such failure shall remain un-remedied for [ *** ] after written notice
to the breaching party by the other party. Upon an Event of Termination for
Cause the party not responsible may, by [ *** ] advance written notice to the
other party, terminate this Agreement.

        17.3    Events of Termination for Change of Control. The following
events shall constitute events of termination arising from a change of control
of DPI ("Events of Termination for COC"): in the event of either: i) the
transfer of all or substantially all of the assets of DPI by or to a third party
during the term of this Agreement; or ii) a merger or consolidation under which
DPI is not the surviving entity; or iii) any transaction, whether sale of stock,
merger or other transaction, resulting in a change of control of DPI. On any
Event of Termination for COC Pfizer shall have the right to terminate this
Agreement. DPI shall notify Pfizer not later than [ *** ] of the Event of
Termination for COC. If Pfizer intends to exercise its right to termination, it
shall provide DPI written notice of such intention no later than [ *** ] after
Pfizer receives DPI's notification described above. Such termination shall take
effect [ *** ] after Pfizer gives DPI such notice (the "Termination Period").

        17.3.1    Termination Period and Termination Budget. During the
Termination Period DPI shall deliver and provide, and Pfizer shall pay for
[ *** ]. In the case of [ *** ] that [ *** ] by [ *** ] in accordance with the
Annual Project Plan but

*** Confidential Treatment Requested

17

--------------------------------------------------------------------------------

which [ *** ], which [ *** ] in [ *** ] and [ *** ], [ *** ] may deliver to
[ *** ] a [ *** ]. The rate per [ *** ] is [ *** ]. The amounts payable by
Pfizer with respect to activities and deliverables during the Termination
Period, (the "Termination Budget" shall not exceed [ *** ] that [ *** ] [ *** ]
[ *** ] [ *** ]. If the Termination Period straddles the end of a calendar
quarter then the portion equal to the percentage of the time-period of the next
scheduled calendar quarter in the Termination Period shall be included in the
calculation of the number or quantity of [ *** ] that will be provided in the
Termination Period and the Termination Budget. By way of example only, if the
Termination Period began on [ *** ], then the Termination Period would run from
[ *** ] and the Termination Budget would be the [ *** ].

If the Termination Budget would be [ *** ] that are scheduled to be provided
during the Termination Period, then DPI will be required to deliver only those
[ *** ] to the extent necessary to utilize the full, but not exceed, the
Termination Budget. Work done during the Termination Period, will be prioritized
to first, complete work [ *** ] [ *** ] [ *** ] during the Termination Period;
and, second [ *** ] during the Termination Period; and third, the [ *** ] in the
Annual Project Plan for the Termination Period (or as otherwise agreed by the
Steering Committee). The Termination Budget will reflect the work allocation.
Pfizer shall have the right, but not the obligation, [ *** ] to be delivered
during the Termination Period; in which case, provided notice of such increased
budget is included in the notice of termination, DPI will be obligated to
complete the delivery of [ *** ]

        17.4    Termination at Pfizer's Discretion. At any time following the
first anniversary of the Effective Date, Pfizer may terminate this Agreement on
notice to DPI of at least six (6) months. Pfizer may exercise this right of
termination by giving DPI written notice specifying the date on which such
termination shall take effect. The obligations of the parties for services and
payment shall follow subsection 17.3.1 noting that the example would apply by
amending [ *** ] in the last sentence of the first paragraph to read "[ *** ]"
and by amending "[ *** ]" in the same sentence to read "[ *** ]

        17.5    No Prejudice. Termination of this Agreement for any reason shall
be without prejudice to the rights and obligations of the parties provided in
Sections (5), (10), (11), (13) (14), (15), (17), (20), (21), (23) and any other
Sections which provide by terms performance by either party subsequent to
termination including without limitation DPI's right to receive all payments
accrued hereunder up to the date of termination; or any other remedies which
either party may otherwise have.

18.    REPRESENTATIONS AND WARRANTIES.

        Each of DPI and Pfizer represents and warrants to the other as follows:

        18.1    It is a corporation duly organized, validly existing and is in
good standing under the laws of its jurisdiction of incorporation or formation,
is qualified to do business and is in good standing as a foreign corporation in
each jurisdiction in which the conduct of its business or the ownership of its
properties requires such qualification; and it has all requisite power and

*** Confidential Treatment Requested

18

--------------------------------------------------------------------------------

authority, corporate or otherwise, to conduct its business as now being
conducted, to own, lease and operate its properties and to execute, deliver and
perform this Agreement.

        18.2    The execution, delivery and performance by it of this Agreement
have been duly authorized by all necessary corporate action and do not and will
not (a) require any consent or approval of its stockholders beyond the approvals
already obtained, (b) violate any provision of any law, rule, regulations,
order, writ, judgment, injunction, decree, determination or award presently in
effect having applicability to it or any provision of its certificate of
incorporation or by-laws or (c) result in a breach of or constitute a default
under any material agreement, mortgage, lease, license, permit or other
instrument or obligation to which it is a party or by which it or its properties
may be bound or affected.

        18.3    This Agreement is a legal, valid and binding obligation of it
enforceable against it in accordance with its terms and conditions, except as
such enforceability may be limited by applicable bankruptcy, insolvency,
moratorium, reorganization or similar laws, from time to time in effect,
affecting creditor's rights generally.

        18.4    It is not under any obligation to any person, or entity,
contractual or otherwise, that is conflicting or inconsistent in any respect
with the terms of this Agreement or that would impede the diligent and complete
fulfillment of its obligations.

        18.5    It has good and marketable title to or valid leases or licenses
for, all of its properties, rights and assets necessary for the fulfillment of
its responsibilities under the Project Program, subject to no claim of any third
party other than any relevant lessors or licensors.

19.    COVENANTS OF DPI AND PFIZER OTHER THAN REPORTING REQUIREMENTS.

        Throughout the Agreement Period, each of DPI and Pfizer shall:

        19.1    maintain and preserve its corporate existence, rights,
franchises and privileges in the jurisdiction of its incorporation or formation,
and qualify and remain qualified as a foreign corporation in good standing in
each jurisdiction in which such qualification is from time to time necessary or
desirable in view of their business and operations or the ownership of their
properties.

        19.2    comply in all material respects with the requirements of all
applicable laws, rules, regulations and orders of any government authority to
the extent necessary to conduct the Project Program, except for those laws,
rules, regulations, and orders it may be contesting in good faith.

20.    DISCLAIMER AND WARRANTIES.

        20.1    EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH
IN SECTION (18), DPI MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY
KIND, EXPRESS OR IMPLIED, AS TO ANY OTHER MATTER, INCLUDING, WITHOUT LIMITATION
ANY REPRESENTATION, WARRANTY OR GUARANTEE AS TO MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, SATISFACTORY RESULTS BASED UPON RELIANCE THEREON, OR
OTHERWISE, OR

19

--------------------------------------------------------------------------------

THAT THE PROTOCOLS AND/OR COMPOUNDS DELIVERED PURSUANT HERETO OR THAT ANY
PROCESS, PROTOCOL OR COMPOUND DERIVED THEREFROM WILL NOT INFRINGE ANY PATENT,
COPYRIGHT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

21.    INDEMNIFICATION.

        21.1    Pfizer and DPI will indemnify, defend and hold each other, and
their respective officers, directors and agents, harmless for any and all
damages, settlements, costs, legal fees and other expenses incurred in
connection with a claim by a third party against the other party based on any
action or omission of the indemnifying party's agents, employees, or officers
under this Agreement; provided, however, that the foregoing shall not apply
(i) if the claim is found to be based upon the gross negligence, recklessness or
willful misconduct of the party seeking indemnification; or (ii) if such party
fails to give the other party prompt notice of any claim it receives and such
failure materially prejudices the other party with respect to any claim or
action to which its obligation pursuant to this Section applies. If either party
is obligated to indemnify the other party, then the indemnifying party shall in
its sole discretion, choose legal counsel, control the defense of such claim or
action and settle the same on such terms and conditions it deems advisable,
except that it may not settle a claim or action under this Section 21 without
the consent of the indemnified party if such settlement would impose any
monetary obligations on such indemnified party or require such indemnified party
to submit to an injunction or otherwise limit its Affiliates, employees, agents,
officers or directors except as expressly set forth in this Agreement, neither
party guarantees the safety or usefulness of any services or other deliverable
received hereunder or other chemical compounds provided under this Agreement.

22.    NOTICES.

        22.1    All notices shall be in writing mailed via certified mail,
return receipt requested, courier, or facsimile transmission addressed as
follow, or to such other address as may be designated from time to time:

            If to Pfizer:
            [ *** ]

            If to DPI:

            Discovery Partners International
            9640 Towne Centre Drive
            San Diego, CA 92121
            Attn: President
            Fax: 858-455-8088
            Copy to: Chief Financial Officer
            Fax: 858-455-8088

        Notices shall be deemed given as of the date received at the
above-specified address.

23.    GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York.

*** Confidential Treatment Requested

20

--------------------------------------------------------------------------------

24.    MISCELLANEOUS.

        24.1    This Agreement shall be binding upon and inure to the benefit of
the parties and their respective legal representatives, successors and permitted
assigns.

        24.2    Headings. Paragraph headings are inserted for convenience of
reference only and do not form a part of this Agreement.

        24.3    This Agreement may be executed simultaneously in two (2) or more
counterparts, each of which shall be deemed an original. Signatures may be
transmitted via facsimile, thereby constituting the valid signature and delivery
of this Agreement.

        24.4    Amendment Waiver. This Agreement may be amended, modified,
superseded or cancelled, and any of the terms may be waived, only by a written
instrument executed by each party or, in the case of waiver, by the party or
parties waiving compliance. The delay or failure of any party at any time or
times to require performance of any provisions shall in no manner affect the
rights at a later time to enforce the same. No waiver by any party of any
condition or of the breach of any term contained in this Agreement, whether by
conduct, or otherwise, in any one or more instances, shall be deemed to be, or
considered as, a further or continuing waiver of any such condition or of the
breach of such term or any other term of this Agreement.

        24.5    No Third Party Beneficiaries. No third party including any
employee of any party to this Agreement, shall have or acquire any rights by
reason of this Agreement. Nothing contained in this Agreement shall be deemed to
constitute the parties partners with each other or any third party.

        24.6    The parties acknowledge and agree that DPI may cause its
subsidiary, which may or may not be ChemRx Advanced Technologies, Inc. to
perform DPI's obligations under this Agreement.

        24.7    Entire Agreement. This Agreement shall govern with respect to
its subject matter from and after its Effective Date and shall supercede with
respect to such subject matter all other agreements in so far as they would
otherwise operate from and after the Effective Date; but however, shall not
affect such agreements with respect to the parties' rights and obligations
accrued there under up to the Effective Date.

        24.8    Assignment and Successors. Subject to the terms and condition of
Section (17.3), this Agreement may not be assigned by either party without the
prior written consent of the other, except that Pfizer may assign this Agreement
and the rights and interests of such party, in whole or in part, to any of its
Affiliates. Subject to 17.3, DPI may assign this Agreement and the rights and
interests of such party to any purchaser of all of its assets or to any
successor corporation resulting from any merger of consolidation of such party
with or into such corporations.

        24.9    Neither Pfizer nor DPI shall be liable for failure of or delay
in performing obligations set forth in this Agreement, and neither shall be
deemed in breach of its obligations, if such failure or delay is due to natural
disasters or any causes reasonably beyond the control of Pfizer or DPI.

21

--------------------------------------------------------------------------------

        24.10    If any provision of this Agreement is or becomes invalid or is
ruled invalid by any court of competent jurisdiction or is deemed unenforceable,
it is the intention of the parties that the remainder of the Agreement shall not
be affected so long as the essential benefits of this Agreement remain
enforceable and obtainable.

        IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their duly authorized representatives.

Agreed: Discovery Partners International, Inc   Agreed: Pfizer Inc
By:
 
/s/  RICCARDO PIGLIUCCI      

--------------------------------------------------------------------------------

 
By:
 
/s/  DR. JOHN LAMATTINA      

--------------------------------------------------------------------------------

Name:
 
Riccardo Pigliucci
 
Name:
 
Dr. John LaMattina
Title:
 
Chairman and CEO
 
Title:
 
President, PGRD
Date:
 
2/13/04

--------------------------------------------------------------------------------

 
Date:
 
2/13/04

--------------------------------------------------------------------------------

22

--------------------------------------------------------------------------------

EXHIBIT A
To the Agreement between Pfizer Inc and
Discovery Partners International, Inc.
executed on January 5, 2004.

[ *** ] Annual Project Plan and [ *** ]

Product Classifications

        The plan for the collaboration between Pfizer, Inc and Discovery
Partners International, Inc. (DPI) includes components of [ *** ].

Table 1

[ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]

Service for the Classes of Products

        1. FE:    Pfizer will provide DPI with [ *** ]. DPI will use [ *** ] to
[ *** ] of [ *** ] to ensure that the [ *** ] have [ *** ] by [ *** ] [ *** ].
When it is agreed that [ *** ] in [ *** ], the [ *** ]. The [ *** ] will be
[ *** ]. Currently the [ *** ] Annual Project Plan.

        2. LL:    Pfizer will provide DPI with [ *** ]. DPI will [ *** ]. When
it is agreed that [ *** ] is [ *** ] in making the [ *** ]. The [ *** ] will be
prioritized by the [ *** ]

        3. HF:    Pfizer will provide DPI with a [ *** ] and a [ *** ] in a
[ *** ] for [ *** ] DPI will [ *** ] and [ *** ] of [ *** ] to [ *** ] to
[ *** ]. When it is agreed that [ *** ] will [ *** ]. When these [ *** ] will
[ *** ]. The [ *** ] will be [ *** ].

        4. MT:    Pfizer will provide DPI with [ *** ]DPI will [ *** ]When it is
agreed that [ *** ]the[ *** ] The [ *** ]will be [ *** ].

        5. Other Services:    From time to time the parties may agree to perform
Other Services. Such work as described on the appropriate Work Order will be
monitored by the Steering Committee.

*** Confidential Treatment Requested

23

--------------------------------------------------------------------------------

Collaboration Goals and Budgets

        Targeted deliverables for the [ *** ] Annual Project Plan and the
[ *** ] Annual Budget are shown in Table 2. Targeted deliverables for the
[ *** ] Annual Project Plan and the annual budget for [ *** ] are shown in Table
3. The parties acknowledge that at the time of execution of this Agreement,
[ *** ] has [ *** ] in the [ *** ] Annual Budget. The goals in the Annual
Project Plan and the allocation of the budget may be modified by the Steering
Committee during the course of the collaboration as allowed by the contractual
terms in Section 2 and 3 of the Agreement.

Table 2 [ *** ]

[ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
 
[ *** ]
 
 
 
 
 
 
 
 
 
 
 
 
 
[ *** ]

[ *** ]

[ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
[ *** ]
[ *** ]
 
 
 
 
 
 
 
 
 
 
 
 
 
[ *** ]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
 
 
 
 
[ *** ]

*The unit price of [ *** ] For the quarterly budgeted amount, [ *** ] agreed to
by the Steering Committee subject to section 2.2.2.

        ^A[ *** ]

*** Confidential Treatment Requested

24

--------------------------------------------------------------------------------

Collaboration Management

        Steering Committee:    Refer to the Agreement for the roles and
responsibilities of the Steering Committee per Section 6.

        Working Groups:    Four (4) initial working groups will be formed to
manage activity toward each of the [ *** ] product types ([ *** ]). Each working
group will be lead by one (1) Pfizer and one (1) DPI appointee. Working groups
will meet weekly or biweekly by teleconference to handle daily communication,
scientific and technical issues, and project prioritisation within the Group.
Working group leaders will be responsible for communicating progress toward
goals and major issues to the Research Contacts in a proactive manner.

Record Keeping:

        1.    A database record of [ *** ] that includes [ *** ] that are
[ *** ], [ *** ], and [ *** ] to be [ *** ]. This [ *** ] will be [ *** ] to
[ *** ]. [ *** ].

        2.    A database record of [ *** ] that includes [ *** ] This
[ *** ]will be [ *** ].

        3.    A database record of [ *** ] This [ *** ] will be [ *** ].

        4.    A database record of [ *** ] This [ *** ] will be [ *** ].

        5.    [ *** ] 6. A database record of [ *** ] will be [ *** ] 7. [ *** ]
8. [ *** ] 9. [ *** ]

*** Confidential Treatment Requested

25

--------------------------------------------------------------------------------

EXHIBIT B
To the Agreement between Pfizer Inc and
Discovery Partners International, Inc.
executed on January 5, 2004.

Work Orders

[ *** ]

*** Confidential Treatment Requested

26

--------------------------------------------------------------------------------

SPECIFICATIONS SCHEDULE

[ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

  [ *** ]

--------------------------------------------------------------------------------

[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]
 
[ *** ]

*** Confidential Treatment Requested

27

--------------------------------------------------------------------------------

QuickLinks

Chemistry Products and Services Agreement
[ *** ] Annual Project Plan and [ *** ]
EXHIBIT B To the Agreement between Pfizer Inc and Discovery Partners
International, Inc. executed on January 5, 2004.
Work Orders
SPECIFICATIONS SCHEDULE